GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Future Medicine Co Ltd (XKRX:341170) » Definitions » PS Ratio

Future Medicine Co (XKRX:341170) PS Ratio : (As of Dec. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Future Medicine Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Future Medicine Co's share price is ₩1850.00. Future Medicine Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.00. Hence, Future Medicine Co's PS Ratio for today is .

The historical rank and industry rank for Future Medicine Co's PS Ratio or its related term are showing as below:

During the past 9 years, Future Medicine Co's highest PS Ratio was 69.54. The lowest was 13.89. And the median was 40.77.

XKRX:341170's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.73
* Ranked among companies with meaningful PS Ratio only.

Future Medicine Co's Revenue per Sharefor the six months ended in Dec. 2023 was ₩0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.00.

During the past 9 years, Future Medicine Co's highest 3-Year average Revenue per Share Growth Rate was 151.90% per year. The lowest was -56.50% per year. And the median was 47.70% per year.

Back to Basics: PS Ratio


Future Medicine Co PS Ratio Historical Data

The historical data trend for Future Medicine Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Future Medicine Co PS Ratio Chart

Future Medicine Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

Future Medicine Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Future Medicine Co's PS Ratio

For the Biotechnology subindustry, Future Medicine Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Future Medicine Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Future Medicine Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Future Medicine Co's PS Ratio falls into.



Future Medicine Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Future Medicine Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1850.00/0
=

Future Medicine Co's Share Price of today is ₩1850.00.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Future Medicine Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Future Medicine Co  (XKRX:341170) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Future Medicine Co PS Ratio Related Terms

Thank you for viewing the detailed overview of Future Medicine Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Future Medicine Co Business Description

Traded in Other Exchanges
N/A
Address
54 changup-ro, Rm 616 LH-Business Growth Center, Gyeonggi-do, Sujeong-gu, Seongnam, KOR, 13449
Future Medicine Co Ltd is a drug development company. It engages in the development of new drug candidates for anti-inflammatory/anti-fibrosis of non-alcoholic hepatitis (NASH) drugs, oral glaucoma treatments, and chronic kidney disease treatments, as well as targeted and Immuno cancer drugs.

Future Medicine Co Headlines

No Headlines